Green Cross Medical Science Corporation
Green Cross Medical Science Corporation manufactures and sells diagnostic reagents and medical devices in South Korea and internationally. The company offers immunology diagnostic reagents. It also provides COVID-19 kit; blood glucose monitoring system; HbA1c test machine; and Gcare LIPID and LIPID printer. Green Cross Medical Science Corporation was founded in 1972 and is headquartered in Yongin… Read more
Green Cross Medical Science Corporation (142280) - Total Liabilities
Latest total liabilities as of September 2025: ₩49.85 Billion KRW
Based on the latest financial reports, Green Cross Medical Science Corporation (142280) has total liabilities worth ₩49.85 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Green Cross Medical Science Corporation - Total Liabilities Trend (2014–2024)
This chart illustrates how Green Cross Medical Science Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Green Cross Medical Science Corporation Competitors by Total Liabilities
The table below lists competitors of Green Cross Medical Science Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DIVA Laboratories Ltd
TWO:4153
|
Taiwan | NT$422.17 Million |
|
PT Wijaya Karya (Persero) Tbk
F:5AA
|
Germany | €48.44 Trillion |
|
Taiwan Name Plate Co. Ltd.
TWO:6593
|
Taiwan | NT$390.25 Million |
|
H.H.Galaxy Co., Ltd.
TWO:2949
|
Taiwan | NT$1.32 Billion |
|
Thantawan Industry Public Company Limited
BK:THIP
|
Thailand | ฿1.55 Billion |
|
Cobre Ltd
AU:CBE
|
Australia | AU$6.80 Million |
|
Berjaya Assets Bhd
KLSE:3239
|
Malaysia | RM1.21 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Green Cross Medical Science Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Green Cross Medical Science Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Green Cross Medical Science Corporation (2014–2024)
The table below shows the annual total liabilities of Green Cross Medical Science Corporation from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩46.76 Billion | -12.77% |
| 2023-12-31 | ₩53.61 Billion | -15.20% |
| 2022-12-31 | ₩63.22 Billion | +6.22% |
| 2021-12-31 | ₩59.51 Billion | +21.12% |
| 2020-12-31 | ₩49.14 Billion | +25.06% |
| 2019-12-31 | ₩39.29 Billion | -19.21% |
| 2018-12-31 | ₩48.63 Billion | +30.35% |
| 2017-12-31 | ₩37.31 Billion | +1.50% |
| 2016-12-31 | ₩36.76 Billion | -15.97% |
| 2015-12-31 | ₩43.74 Billion | +112.38% |
| 2014-12-31 | ₩20.60 Billion | -- |